Abstract
Background: Beyond prostate-specific antigen (PSA), other biomarkers for prostate cancer (PCa) detection are available and need to be evaluated for clinical routine. Objective: The aim of the study was to evaluate the Prostate Health Index (PHI) density (PHID) in comparison with PHI in a large Caucasian group >1,000 men. Methods: PHID values were used from available patient data with PSA, free PSA, and [−2]pro-PSA and prostate volume from 3 former surveys from 2002 to 2014. Those 1,446 patients from a single-center cohort included 701 men with PCa and 745 with no PCa. All patients received initial or repeat biopsies. The diagnostic accuracy was evaluated by receiver operating characteristic (ROC) curves comparing area under the ROC curves (AUCs), precision-recall approach, and decision curve analysis (DCA). Results: PHID medians differed almost 2-fold between PCa (1.12) and no PCa (0.62) in comparison to PHI (48.6 vs. 33; p always <0.0001). However, PHID and PHI were equal regarding the AUC (0.737 vs. 0.749; p = 0.226), and the curves of the precision-recall analysis also overlapped in the sensitivity range between 70 and 100%. DCA had a maximum net benefit of only ∼5% for PHID versus PHI between 45 and 55% threshold probability. Contrary, in the 689 men with a prostate volume ≤40 cm3, PHI (AUC 0.732) showed a significant larger AUC than PHID (AUC 0.69, p = 0.014). Conclusions: Based on DCA, PHID had only a small advantage in comparison with PHI alone, while ROC analysis and precision-recall analysis showed similar results. In smaller prostates, PHI even outperformed PHID. The increment for PHID in this large Caucasian cohort is too small to justify a routine clinical use.
References
1.
Albertsen
PC
. Prostate cancer screening and treatment: where have we come from and where are we going?
BJU Int
. 2020
;126
(2
):218
–24
. .2.
Catalona
WJ
. Prostate cancer screening
. Med Clin North Am
. 2018
;102
(2
):199
–214
. .3.
Mikolajczyk
SD
, Marker
KM
, Millar
LS
, Kumar
A
, Saedi
MS
, Payne
JK
, A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer
. Cancer Res
. 2001
;61
(18
):6958
–63
.4.
Catalona
WJ
, Partin
AW
, Sanda
MG
, Wei
JT
, Klee
GG
, Bangma
CH
, A multicenter study of [−2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range
. J Urol
. 2011
;185
(5
):1650
–5
. .5.
Ferro
M
, De Cobelli
O
, Lucarelli
G
, Porreca
A
, Busetto
GM
, Cantiello
F
, Beyond PSA: the role of prostate health index (phi)
. Int J Mol Sci
. 2020
;21
:1184
.6.
Lazzeri
M
, Haese
A
, de la Taille
A
, Palou Redorta
J
, McNicholas
T
, Lughezzani
G
, Serum isoform [−2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/mL: a multicentric European study
. Eur Urol
. 2013
;63
(6
):986
–94
. .7.
Mearini
L
, Ferri
C
, Lazzeri
M
, Bini
V
, Nunzi
E
, Fiorini
D
, Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study
. Urol Int
. 2014
;93
(2
):135
–45
. .8.
Druskin
SC
, Tosoian
JJ
, Young
A
, Collica
S
, Srivastava
A
, Ghabili
K
, Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer
. BJU Int
. 2018
;121
(4
):619
–26
. .9.
Lopes Vendrami
C
, McCarthy
RJ
, Chatterjee
A
, Casalino
D
, Schaeffer
EM
, Catalona
WJ
, The utility of prostate specific antigen density, prostate health index and prostate health index density in predicting positive prostate biopsy outcome is dependent on the prostate biopsy methods
. Urology
. 2019
;129
:159
.10.
Tosoian
JJ
, Druskin
SC
, Andreas
D
, Mullane
P
, Chappidi
M
, Joo
S
, Prostate health index density improves detection of clinically significant prostate cancer
. BJU Int
. 2017
;120
(6
):793
–8
. .11.
Friedl
A
, Stangl
K
, Bauer
W
, Kivaranovic
D
, Schneeweiss
J
, Susani
M
, Prostate-specific antigen parameters and Prostate Health Index enhance prostate cancer prediction with the in-bore 3-t magnetic resonance imaging-guided transrectal targeted prostate biopsy after negative 12-core biopsy
. Urology
. 2017
;110
:148
–53
. .12.
Schulze
A
, Christoph
F
, Sachs
M
, Schroeder
J
, Stephan
C
, Schostak
M
, Use of the prostate health index and density in 3 outpatient centers to avoid unnecessary prostate biopsies
. Urol Int
. 2020
;104
(3–4
):181
–6
. .13.
Barisiene
M
, Bakavicius
A
, Stanciute
D
, Jurkeviciene
J
, Zelvys
A
, Ulys
A
, Prostate health index and prostate health index density as diagnostic tools for improved prostate cancer detection
. Biomed Res Int
. 2020
;2020
:9872146
. .14.
Huang
D
, Wu
YS
, Ye
DW
, Qi
J
, Liu
F
, Helfand
BT
, Prostate volume does not provide additional predictive value to prostate health index for prostate cancer or clinically significant prostate cancer: results from a multicenter study in China
. Asian J Androl
. 2020 Sep–Oct
;22
(5
):539
–43
. .15.
Stephan
C
, Kahrs
AM
, Cammann
H
, Lein
M
, Schrader
M
, Deger
S
, A [−2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases
. Prostate
. 2009
;69
(2
):198
–207
. .16.
Stephan
C
, Vincendeau
S
, Houlgatte
A
, Cammann
H
, Jung
K
, Semjonow
A
. Multicenter evaluation of [−2]proprostate-specific antigen and the prostate health index for detecting prostate cancer
. Clin Chem
. 2013
;59
(1
):306
–14
. .17.
Stephan
C
, Lein
M
, Matalon
J
, Kilic
E
, Zhao
Z
, Busch
J
, Serum vitamin D is not helpful for predicting prostate cancer aggressiveness compared with the prostate health index
. J Urol
. 2016
;196
(3
):709
–14
. .18.
Dittadi
R
, Fabricio
ASC
, Rainato
G
, Peroni
E
, Di Tonno
F
, Vezzù
B
, Preanalytical stability of [−2]proPSA in whole blood stored at room temperature before separation of serum and plasma: implications to Phi determination
. Clin Chem Lab Med
. 2019
;57
(4
):521
–31
. .19.
Igawa
T
, Takehara
K
, Onita
T
, Ito
K
, Sakai
H
. Stability of [−2]Pro-PSA in whole blood and serum: analysis for optimal measurement conditions
. J Clin Lab Anal
. 2014
;28
(4
):315
–9
. .20.
Semjonow
A
, Köpke
T
, Eltze
E
, Pepping-Schefers
B
, Bürgel
H
, Darte
C
. Pre-analytical in-vitro stability of [−2]proPSA in blood and serum
. Clin Biochem
. 2010
;43
(10–11
):926
–8
. .21.
DeLong
ER
, DeLong
DM
, Clarke-Pearson
DL
. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach
. Biometrics
. 1988
;44
(3
):837
–45
. .22.
Saito
T
, Rehmsmeier
M
. The precision-recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced datasets
. PLoS One
. 2015
;10
(3
):e0118432
. .23.
Stephan
C
, Jung
K
, Semjonow
A
, Schulze-Forster
K
, Cammann
H
, Hu
X
, Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [−2]proprostate-specific antigen-based prostate health index for detection of prostate cancer
. Clin Chem
. 2013
;59
(1
):280
–8
. .24.
Vickers
AJ
, Elkin
EB
. Decision curve analysis: a novel method for evaluating prediction models
. Med Decis Making
. 2006 Nov–Dec
;26
(6
):565
–74
. .25.
Filella
X
, Foj
L
, Alcover
J
, Augé
JM
, Molina
R
, Jiménez
W
. The influence of prostate volume in prostate health index performance in patients with total PSA lower than 10 μg/L
. Clin Chim Acta
. 2014
;436
:303
–7
. .26.
Stephan
C
, Jung
K
, Lein
M
, Rochow
H
, Friedersdorff
F
, Maxeiner
A
. PHI density prospectively improves prostate cancer detection
. World J Urol
. 2021 Jan 20
. Online ahead of print.27.
Filella
X
, Foj
L
. Novel biomarkers for prostate cancer detection and prognosis
. Adv Exp Med Biol
. 2018
;1095
:15
–39
. .28.
Zhang
G
, Li
Y
, Li
C
, Li
N
, Li
Z
, Zhou
Q
. Assessment on clinical value of prostate health index in the diagnosis of prostate cancer
. Cancer Med
. 2019
;8
(11
):5089
–96
. .29.
Chiu
PK
, Ng
CF
, Semjonow
A
, Zhu
Y
, Vincendeau
S
, Houlgatte
A
, A multicentre evaluation of the role of the Prostate Health Index (PHI) in regions with differing prevalence of prostate cancer: adjustment of PHI reference ranges is needed for european and asian settings
. Eur Urol
. 2019
;75
(4
):558
–61
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
